Methylphenidate Hydrochloride ER
DrugMethylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
NCT Number: NCT05469386
This study is the first to systematically evaluate the efficacy of single and combined academic accommodation, behavioral treatment, and medication treatment in a large sample of children with ADHD. Using a scientifically rigorous, cross-over design the impact of these approaches on ecologically valid measures of outcome (on-task behavior, quiz scores, academic productivity) will be assessed to inform effective school intervention.
This study is active but is not currently recruiting participants.
Notify Me5 year–12 year
All sexes
Interventional
Phase 4
FIU Center for Childern and Families, Miami, Florida, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
Enhanced positive behavior supports implemented in classroom
Placebo capsule
General education classroom procedures
Accommodations are introduced to support the child's independent seat work completion and quiz scores
Time frame: Through study completion, a maximum of eight weeks
Behavioral frequency count of rule violations. Lower scores are better.
Time frame: Through study completion, a maximum of eight weeks
Percentage of assigned seat work items completed correctly. Range of scores is from 0-100%. Higher scores are better.
Time frame: Through study completion, a maximum of eight weeks
Percentage correct out of 10 quiz questions. Range of scores is from 0-100%. Higher scores are better.
Florida International University
Other
Single and Combined Effects of Positive Behavior Support, Medication and Academic Accommodation for Children With ADHD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06711224
ADHD, Attention Deficit Disorder with Hyperactivity
Bergen, Norway
View Trial DetailsNCT06189703
ADHD, Attention Deficit Disorder with Hyperactivity
Boston, Massachusetts, United States
View Trial DetailsNCT06036420
ADHD, Attention Deficit Disorder with Hyperactivity
Los Angeles, California, United States
View Trial DetailsNCT05102864
ADHD, Attention Deficit Disorder with Hyperactivity
East Providence, Rhode Island, United States
View Trial Details